stockrow
Saturday 7 November 2026
Export VOGX’s income statement to Excel — free account
Vogenx Inc
VOGX Healthcare Biotechnology
17.45
0.78
−4.28%
Follow VOGX
Alert me
| Jun '25 | Dec '25 | Jun '26 | |
|---|---|---|---|
Current Ratio |
— | 0.43 | 0.44 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.54 |
Debt/Assets |
— | 0.00% | 0.00% |
Debt/Equity |
— | 0.00 | 0.00 |
Operating CF/Net income |
0.00 | — | 0.00 |
Research and Development Expense of Revenue |
0.00% | — | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | — | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 |
Free Cash Flow per Share |
0.00 | — | 0.00 |
Cash per Share |
0.00 | 0.00 | 0.04 |
Shareholders Equity per Share |
0.00 | 0.00 | (0.33) |
Interest Debt per Share |
0.00 | — | 0.00 |
Book value per Share |
0.00 | 0.00 | (0.33) |
| Other line items | |||
Quick Ratio |
— | 0.38 | 0.06 |
Revenue per Share |
0.00 | — | 0.00 |
Operating CF per Share |
0.00 | — | 0.00 |
Capex per Share |
0.00 | — | 0.00 |
Working Capital |
— | (0.92) | (1.78) |
Net Current Asset Value |
— | (0.92) | (1.78) |
Columns are period end dates · fundamentals updated 2 Nov 2026